189 related articles for article (PubMed ID: 8883963)
1. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Alonso DF; Farías EF; Ladeda V; Davel L; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 1996; 40(3):209-23. PubMed ID: 8883963
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF
Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.
Alonso DF; Tejera AM; Farias EF; Bal de Kier Joffe E; Gomez DE
Anticancer Res; 1998; 18(6A):4499-504. PubMed ID: 9891516
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
5. Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Evans DM; Sloan-Stakleff KD
Invasion Metastasis; 1998-1999; 18(5-6):252-60. PubMed ID: 10729770
[TBL] [Abstract][Full Text] [Related]
6. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428.
Evans DM; Sloan-Stakleff K
Am Surg; 2000 May; 66(5):460-4. PubMed ID: 10824746
[TBL] [Abstract][Full Text] [Related]
7. Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.
Swiercz R; Skrzypczak-Jankun E; Merrell MM; Selman SH; Jankun J
Oncol Rep; 1999; 6(3):523-6. PubMed ID: 10203585
[TBL] [Abstract][Full Text] [Related]
8. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
9. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
10. Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma.
Alonso DF; Farías EF; Urtreger A; Ladeda V; Vidal MC; Bal De Kier Joffé E
J Surg Oncol; 1996 Aug; 62(4):288-97. PubMed ID: 8691844
[TBL] [Abstract][Full Text] [Related]
11. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
12. Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: enhancement by paclitaxel and inhibition by nocodazole.
Alonso DF; Farina HG; Arregui C; Aon MA; Gomez DE
Int J Cancer; 1999 Oct; 83(2):242-6. PubMed ID: 10471534
[TBL] [Abstract][Full Text] [Related]
13. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
[TBL] [Abstract][Full Text] [Related]
14. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T
Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966
[TBL] [Abstract][Full Text] [Related]
16. Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.
Evans DM; Sloan Stakleff KD
Clin Exp Metastasis; 2004; 21(4):339-46. PubMed ID: 15554390
[TBL] [Abstract][Full Text] [Related]
17. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
18. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability.
Guerra FK; Eijan AM; Puricelli L; Alonso DF; Bal de Kier Joffé E; Kornblihgtt AR; Charreau EH; Elizalde PV
Int J Cancer; 1996 Mar; 65(6):812-20. PubMed ID: 8631597
[TBL] [Abstract][Full Text] [Related]
19. Verapamil inhibits tumor protease production, local invasion and metastasis development in murine carcinoma cells.
Farías EF; Aguirre Ghiso JA; Ladeda V; Bal de Kier Joffé E
Int J Cancer; 1998 Dec; 78(6):727-34. PubMed ID: 9833766
[TBL] [Abstract][Full Text] [Related]
20. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Oh SH; Lee OH; Schroeder CP; Oh YW; Ke S; Cha HJ; Park RW; Onn A; Herbst RS; Li C; Lee HY
Mol Cancer Ther; 2006 Nov; 5(11):2685-95. PubMed ID: 17121915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
